Immunotherapy-based combination approaches for HPV-associated cancers — the PD-1/PD-L1 checkpoint inhibitors combined with chemoradiotherapy, therapeutic vaccines, and novel biologics representing the fastest-evolving treatment landscape in the global HPV disorder management space — creates the most clinically transformative market segment, with the HPV-associated Disorder Market...